These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30777112)

  • 1. Community perspectives on treating asymptomatic infections for malaria elimination in The Gambia.
    Jaiteh F; Masunaga Y; Okebe J; D'Alessandro U; Balen J; Bradley J; Gryseels C; Ribera JM; Grietens KP
    Malar J; 2019 Feb; 18(1):39. PubMed ID: 30777112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive, self-administered malaria treatment against asymptomatic malaria infection: results of a cluster randomized controlled trial in The Gambia.
    Okebe J; Dabira E; Jaiteh F; Mohammed N; Bradley J; Drammeh NF; Bah A; Masunaga Y; Achan J; Muela Ribera J; Yeung S; Balen J; Peeters Grietens K; D'Alessandro U
    Malar J; 2021 Jun; 20(1):253. PubMed ID: 34098984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Non-Participation and Non-Adherence in Directly Observed Mass Drug Administration for Malaria in The Gambia.
    Dierickx S; Gryseels C; Mwesigwa J; O'Neill S; Bannister-Tyrell M; Ronse M; Jaiteh F; Gerrets R; D'Alessandro U; Grietens KP
    PLoS One; 2016; 11(2):e0148627. PubMed ID: 26866685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding adherence to reactive treatment of asymptomatic malaria infections in The Gambia.
    Jaiteh F; Okebe J; Masunaga Y; D'Alessandro U; Achan J; Gryseels C; de Vries D; Ribera JM; Grietens KP
    Sci Rep; 2021 Jan; 11(1):1746. PubMed ID: 33462329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acceptability of mass administrations of anti-malarial drugs as part of targeted malaria elimination in villages along the Thai-Myanmar border.
    Kajeechiwa L; Thwin MM; Shee PW; Yee NL; Elvina E; Peapah P; Kyawt K; Oo PT; PoWah W; Min JR; Wiladphaingern J; von Seidlein L; Nosten S; Nosten F
    Malar J; 2016 Sep; 15(1):494. PubMed ID: 27677694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cluster-randomized trial of monthly malaria prophylaxis versus focused screening and treatment: a study protocol to define malaria elimination strategies in Cambodia.
    Manning J; Lon C; Spring M; Wojnarski M; Somethy S; Chann S; Gosi P; Soveasna K; Sriwichai S; Kuntawunginn W; Fukuda MM; Smith PL; Rekol H; Sinoun M; So M; Lin J; Satharath P; Saunders D
    Trials; 2018 Oct; 19(1):558. PubMed ID: 30326952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia.
    Fehr A; Nieto-Sanchez C; Muela J; Jaiteh F; Ceesay O; Maneh E; Baldeh D; Achan J; Dabira E; Conteh B; Bunders-Aelen J; Smekens T; Broekhuizen H; D'Alessandro U; Peeters Grietens K
    Malar J; 2021 Apr; 20(1):198. PubMed ID: 33902611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-led Responses for Elimination (CoRE): a study protocol for a community randomized controlled trial assessing the effectiveness of community-level, reactive focal drug administration for reducing Plasmodium falciparum infection prevalence and incidence in Southern Province, Zambia.
    Bridges DJ; Miller JM; Chalwe V; Moonga H; Hamainza B; Steketee R; Silumbe K; Nyangu J; Larsen DA
    Trials; 2017 Nov; 18(1):511. PubMed ID: 29096671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and
    Finn TP; Porter TR; Moonga H; Silumbe K; Daniels RF; Volkman SK; Yukich JO; Keating J; Bennett A; Steketee RW; Miller JM; Eisele TP
    Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):37-45. PubMed ID: 32618267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial.
    Okebe J; Bousema T; Affara M; Di Tanna GL; Dabira E; Gaye A; Sanya-Isijola F; Badji H; Correa S; Nwakanma D; Van Geertruyden JP; Drakeley C; D'Alessandro U
    EBioMedicine; 2016 Nov; 13():348-355. PubMed ID: 27825738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study.
    Mwesigwa J; Achan J; Affara M; Wathuo M; Worwui A; Mohammed NI; Kanuteh F; Prom A; Dierickx S; di Tanna GL; Nwakanma D; Bousema T; Drakeley C; Van Geertruyden JP; D'Alessandro U
    Clin Infect Dis; 2019 Jul; 69(2):278-286. PubMed ID: 30304511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative study to identify community structures for management of severe malaria: a basis for introducing rectal artesunate in the under five years children in Nakonde District of Zambia.
    Kaona FA; Tuba M
    BMC Public Health; 2005 Mar; 5():28. PubMed ID: 15792501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania.
    Baiden R; Oduro A; Halidou T; Gyapong M; Sie A; Macete E; Abdulla S; Owusu-Agyei S; Mulokozi A; Adjei A; Sevene E; Compaoré G; Valea I; Osei I; Yawson A; Adjuik M; Akparibo R; Ogutu B; Upunda GL; Smith P; Binka F
    Malar J; 2015 Apr; 14():160. PubMed ID: 25885858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why do people participate in mass anti-malarial administration? Findings from a qualitative study in Nong District, Savannakhet Province, Lao PDR (Laos).
    Adhikari B; Phommasone K; Kommarasy P; Soundala X; Souvanthong P; Pongvongsa T; Henriques G; Newton PN; White NJ; Day NPJ; Dondorp AM; von Seidlein L; Mayxay M; Cheah PY; Pell C
    Malar J; 2018 Jan; 17(1):15. PubMed ID: 29316932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
    Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
    Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial.
    Eisele TP; Silumbe K; Finn T; Chalwe V; Kamuliwo M; Hamainza B; Moonga H; Bennett A; Yukich J; Keating J; Steketee RW; Miller JM
    Trials; 2015 Aug; 16():347. PubMed ID: 26268804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous artesunate plus oral dihydroartemisinin-piperaquine or intravenous quinine plus oral quinine for optimum treatment of severe malaria: lesson learnt from a field hospital in Timika, Papua, Indonesia.
    Sikora SA; Poespoprodjo JR; Kenangalem E; Lampah DA; Sugiarto P; Laksono IS; Ahmad RA; Murhandarwati EEH
    Malar J; 2019 Dec; 18(1):448. PubMed ID: 31888655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial.
    Staedke SG; Maiteki-Sebuguzi C; Rehman AM; Kigozi SP; Gonahasa S; Okiring J; Lindsay SW; Kamya MR; Chandler CIR; Dorsey G; Drakeley C
    Lancet Glob Health; 2018 Jun; 6(6):e668-e679. PubMed ID: 29661635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
    McLean ARD; Indrasuta C; Khant ZS; Phyo AK; Maung SM; Heaton J; Aung H; Aung Y; Soe K; Swe MMM; von Seidlein L; Tun NN; Tun KM; Day NPJ; Ashley EA; Hlaing T; Kyaw TT; Dondorp AM; Imwong M; White NJ; Smithuis FM
    Lancet Infect Dis; 2021 Nov; 21(11):1579-1589. PubMed ID: 34147154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.